Ginkgo Bioworks said after the close of the market on Monday that it has raised its full-year 2022 revenue guidance to between $460 million and $480 million, up from previous guidance of between $425 million and $440 million, driven by strength in the firm's biosecurity business.

PerkinElmer said Monday it had secured US Food and Drug Administration authorization to market an assay for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.

SomaLogic reported on Monday that it has recorded a one-time licensing royalty of $21.2 million related to a deal with New England Biolabs.

Roche has begun over-the-counter sales of its at-home COVID-19 rapid antigen test in the U.S.

GE HealthCare has priced an offering of $8.25 billion senior notes in conjunction with the spinoff from its parent company.

Recently, EasyDiagnosis disclosed its third quarterly report, the company achieved revenue of 7.47 billion CNY in the first three quarters, an increase of 285.38% year-on-year; achieved net profit of 3.838 billion CNY, an increase of 281.76% year-on-year.

Becton Dickinson Fiscal Q4 Revenues Decline 2 Percent

The US Food and Drug Administration this week granted Emergency Use Authorization for Nanobiosym Precision Testing Services' Nano Test for COVID-19.

The US Food and Drug Administration last week granted Emergency Use Authorization for Rize Laboratory's SARS nCoV-2019 Multiplexed Assay.

Italian diagnostics firm DiaSorin said on Wednesday that it has received 510(k) clearance from the US Food and Drug Administration for its Simplexa Congenital CMV Direct kit for the detection of cytomegalovirus (CMV) DNA.

Wondfo (300482.SZ) released its third quarter report for 2022. The company's revenue in the first three quarters was CNY 4.696 billion, up 87.32% year-on-year; net profit attributable to the mother company was CNY 1.240 billion

PerkinElmer reported Tuesday its fiscal third quarter revenues dropped 17 percent year over year on declines in its COVID-19 business and pandemic-related lockdowns in China that dragged down the firm's diagnostics revenue.

Orders for Pacific Biosciences' new Revio long-read sequencing instrument are already rolling in, just a few weeks after its reveal, the company said this week as it announced a year-over-year decrease in third quarter revenues.

In the first three quarters of 2022, the company achieved revenue of CNY 1.18 billion, an increase of 39.32% year-on-year; net profit of CNY 308 million, an increase of 22.42% year-on-year; net profit of CNY 306 million, an increase of 28.84% year-on-year.

Qiagen reported double-digit year-over-year sales growth in its core non-COVID-related product portfolio on Monday afternoon, prompting the company to raise its full-year guidance.